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Introduction
The continued vigilance in safety monitoring in randomized clinical trials (RCTs) is critical as more
data and experience are accumulated.1 Emerging safety profiles of therapeutic interventions during
longer follow-up may cast doubt on earlier conclusions about benefit-risk assessment.1,2 Along this
line, cumulative meta-analysis has been proposed as a tool to evaluate evidence aggregation. We
retrospectively assessed how cumulative meta-analysis could serve as a safety monitoring tool to
identify the time point when firm evidence for safety concerns of a rare outcome becomes available.
Methods
For this meta-analysis, we assessed the withdrawn polymeric everolimus-eluting coronary
bioresorbable vascular scaffold (BVS) (Absorb; Abbott Vascular). The BVS received CE mark approval
in January 2011 and US Food and Drug Administration approval in July 2016. In September 2017, the
manufacturer voluntarily withdrew the device owing to safety concerns (increased risk of scaffold-
related thrombosis) after it had been available for clinical use for more than 6 years in Europe and 1
year in the US. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-
analyses (PRISMA) reporting guideline.
We retrieved all available reports of RCTs comparing the BVS with metallic everolimus-eluting
stents for percutaneous coronary interventions by searching PubMed, CENTRAL, and websites of
major cardiology meetings occurring before May 31, 2019. Device-related (scaffold or stent) definite
or probable thrombosis was the safety outcome of interest. We used Mantel-Haenszel (fixed-
effects model) cumulative meta-analysis to summarize accumulated rare events over time and
computed odds ratios (ORs) at each time point. All P values are 2-sided, and P < .05 was considered
statistically significant. Analyses were performed using R, version 3.3.2 (The R Foundation for
Statistical Computing).
Figure 1. Recruitment Periods Across Trials Comparing the Absorb Polymeric Everolimus-Eluting Bioresorbable
Vascular Scaffold With the Metallic Everolimus-Eluting Stent



















The horizontal blue boxes indicate the recruitment
period for each individual trial. Diamonds correspond
to the publication of follow-up data for each study over
time. BVS indicates bioresorbable vascular scaffolds;
FDA, US Food and Drug Administration.
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Results
A total of 22 reports describing 8 RCTs including 8180 patients randomized to BVS (4553 patients) or
everolimus-eluting stents (3627 patients) were included, with 96 and 20 device-related thromboses
for each intervention, respectively. Patient recruitment took place over 6 years, with considerable
overlap of recruitment periods (Figure 1). The cumulative meta-analysis (Figure 2) revealed that the
initial uncertainty regarding the treatment effect based on early trials with follow-up to 1 year gained
precision through inclusion of additional trials and follow-up time. The analysis of accumulated
evidence showed initial safety concerns after the publication of ABSORB III trial on October 12, 2015,
for a clinically important but non–statistically significant increase in the risk of device-related
thrombosis after use of BVS (OR, 2.22; 95% CI, 0.97-5.06, P = .06). The between-group difference
became statistically significant on September 18, 2016 (OR, 2.52; 95% CI, 1.12-5.71; P = .03).
Availability of longer follow-up and new trials resulted in an OR of 2.87 (95% CI, 1.34-6.16; P = .007)
11 months before the Absorb BVS was withdrawn in September 2017. Between-group differences
reached on March 18, 2017, had an OR of 3.15 (95% CI, 1.48-6.72; P = .003) with a lower limit of the
95% CI above 1.00 (Figure 2). The final estimate was an OR of BVS-related thrombosis of 3.68 (95%
CI, 2.25-6.00; P < .001), indicating that the experimental intervention was harmful.
Figure 2. Cumulative Meta-analysis of Trials Comparing the Absorb Polymeric Everolimus-Eluting Bioresorbable Vascular Scaffold




















.411 y September 14, 2014 501 3ABSORB II 3.51 (0.18-68.30)
CE mark approval (January 2011)
.411 y March 3, 2015 659 3EVERBIO II 3.51 (0.18-68.30)
.481 y September 1, 2015 1057 9ABSORB Japan 1.76 (0.36-8.56)
.331 y September 24, 2015 1248 10TROFI II 2.14 (0.46-10.00)
.231 y October 12, 2015 1723 11ABSORB China 2.53 (0.56-11.50)
.061 y October 12, 2015 3731 36ABSORB III 2.22 (0.97-5.06)
.032 y September 18, 2016 3731 40ABSORB Japan 2.52 (1.12-5.71)
FDA approval (July 2016) 
.022 y October 20, 2016 3731 42ABSORB II 2.67 (1.19-6.02)
.0083 y October 30, 2016 3731 46ABSORB II 2.96 (1.32-6.63)
.0062 y October 31, 2016 3731 47ABSORB China 3.07 (1.38-6.85)
.0072 y October 31, 2016 3731 49TROFI II 2.87 (1.34-6.16)
.0032 y March 18, 2017 3731 53ABSORB III 3.15 (1.48-6.72)
<.0012 y March 29, 2017 5576 92AIDA 3.50 (2.03-6.05)
<.0012 y May 12, 2017 5576 93EVERBIO II 3.56 (2.06-6.14)
BVS withdrawn (September 2017) 
<.0013 y May 16, 2017 5576 94ABSORB Japan 3.60 (2.09-6.20)
<.0013 y October 20, 2017 5576 100ABSORB III 3.82 (2.22-6.58)
<.0013 y October 22, 2017 5576 100ABSORB China 3.82 (2.22-6.58)
<.0014 y October 31, 2017 5576 100ABSORB II 3.82 (2.22-6.56)
<.0013 y October 31, 2017 5576 100TROFI II 3.81 (2.22-6.56)
<.00130 d October 31, 2017 8180 110ABSORB IV 3.84 (2.30-6.41)
<.0011 y September 25, 2018 8180 113ABSORB IV 3.53 (2.16-5.78)
<.0013 y May 23, 2019 8180 116AIDA 3.68 (2.25-6.00)
Reports describing increasing follow-up durations for the same trial are ranked according
to the date of becoming publicly available. To avoid duplicate counts, data from shorter
follow-up periods were omitted from the analysis after data from longer follow-up
periods became available. Squares indicate odds ratios (ORs), with horizontal lines
representing 95% CIs. BVS indicates bioresorbable vascular scaffolds; CE, Conformité
Européene; FDA, US Food and Drug Administration.
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Discussion
Timely recognition of safety signals is important to patients, physicians, regulators, and the medical
community at large to avoid unnecessary, clinically important adverse events and to prevent waste of
research efforts, especially in studies of the comparative effectiveness of medical devices. In the
absence of large clinical trials, some adverse events may not be known a priori when a new device is
used and additional mechanisms, such as regulatory oversight for unexpected events, may be
needed; continuously updated cumulative meta-analyses may contribute to this purpose. Of note,
although cumulative statistical testing can bias this approach, it is not of particular concern in the
present analysis because it was performed retrospectively and was not associated with a stopping
rule for the meta-analysis. However, in a prospectively designed cumulative meta-analysis,
correction for multiple testing should be considered because the examination of multiple outcomes
and repeated analysis of the data over time may exacerbate the risks associated with multiplicity and
further adjustments may be warranted.3,4 Under these scenarios, false-positive rates for significance
tests at the conventional P < .05 are typically too high, and naive interpretations of statistical
significance should be avoided.5,6
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